A study on pre-operative Misoprostol in reducing blood loss in total abdominal hysterectomy

Pre-operative Misoprostol in reducing blood loss in total abdominal hysterectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/091/000216

Enrollment

Registered

2011-02-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- operative blood loss in total abdomonal hysterectomy (TAH)

Interventions

Intervention1: Tab Misoprostol: 400mcg sublingually single dose 30 minutes before TAH Control Intervention1: placebo (vit C tablet): sublingually 30 min before TAH

Eligibility

Inclusion criteria

Inclusion criteria: Symptomatically women undergoing TAH for various benign gynaecological deseases

Exclusion criteria

Exclusion criteria: Any contraindication to misoprostol including mitral stenosis, glaucoma, diastolic blood pressure above 100mm of Hg, asthma, known allergic to prostaglandins

Design outcomes

Primary

Measure	Time frame
Reduction of need for post-operative blood transfusionTimepoint: within 48 hours after surgery	—

Secondary

Measure	Time frame
reduction o post-operative blood lossTimepoint: 48 hours after surgery	—

Countries

India

Contacts

Public ContactDr Jhuma Biswas

drjhumabiswas@yahoo.in033-22041100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 10, 2026